WE.SPEED.
Last week, ARENSIA clinic in Ukraine resumed participation in a Phase I trial with an innovative drug targeting Multiple Sclerosis involving central imaging reading, 3 central laboratories (based in UK and EU), and sophisticated study procedures. Our extraordinary team in Kyiv has dosed the first patient in the MAD cohort. Another 2 patients shall be dosed this week. We plan to progress the project at the fastest speed. Our clinic in Kyiv has access to large pools of neurological patients, including Multiple Sclerosis. We are proud to continue offering Ukrainian patients access to the latest generation therapies!
13.03.2023